BullBearBio translates drug development, clinical evidence, and regulatory science into investor-ready insight, so you understand the asset before the catalyst, not after.
Most sites cover the news. We explain the science, the risk, and the value behind it, the three signals from our mark, turned into a method.
Mechanism of action, trial design, endpoints, and safety signals, read by people who actually understand the biology, not just the headline.
Clinical, regulatory, and dilution risk made explicit. Cash runway, burn rate, and probability-adjusted odds. The bear case stated plainly.
Market size, licensing deals, milestone payments, and a fair valuation range, so a 20 to 100% catalyst move never catches you blind.
A structured library that turns open clinical, regulatory, and scientific sources into something a retail investor can actually act on.
Clinical trial design and readouts decoded from primary registries and the literature.
The decisions that move stocks 20 to 100%, tracked across global agencies.
The mechanisms behind the modalities, explained without the jargon wall.
The metrics most retail investors never learn to read.
Who's ahead, which endpoint matters, and whether the mechanism is validated.
The data drops that reprice biotech overnight, previewed and analyzed.
Ten questions answered for every company we cover, from "does the science actually make sense?" to a defensible fair-value range and a clear investment conclusion. The depth of an analyst desk, written to be understood.
Browse Sample ReportsInteractive instruments that do the heavy analysis for you, the kind of edge that justifies a subscription.
Enter a company and trial, get a phase-success probability, plain-English endpoint explanation, and historical comparators.
Score any name across science, clinical data, regulatory position, financial strength, competition, and valuation.
Upcoming FDA decisions, Phase II/III readouts, and conference dates, every event that can reprice a stock, in one timeline.
Model burn rate against runway to see when, and how badly, a small-cap is likely to raise. Essential for micro-cap investors.
Join investors who read the biology before the press release. Get the weekly catalyst briefing and a free Scientific Due Diligence report.